Colin Nixon

Mr. Colin Nixon

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
JVJohan Vande Voorde
Johan Vande Voorde
TATobias Ackermann
Tobias Ackermann
NPNadja Pfetzer
Nadja Pfetzer
DSDavid Sumpton
David Sumpton
GMGillian Mackay
Gillian Mackay
STSaverio Tardito
Saverio Tardito
Plasmax, a physiological cell culture medium, prevents metabolic artifacts imposed on cancer cells by commonly used media.

7 January 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ANArafath K. Najumudeen
Arafath K. Najumudeen
FCFatih Ceteci
Fatih Ceteci
SFSigrid K. Fey
Sigrid K. Fey
GHGregory Hamm
Gregory Hamm
RSRory T. Steven
Rory T. Steven
OSOwen Sansom
Owen Sansom

2 June 2021 in Nature
Verified
Journal Article
Closed access
PDF file
DFDustin J. Flanagan
Dustin J. Flanagan
NPNalle Pentinmikko
Nalle Pentinmikko
KLKalle Luopajärvi
Kalle Luopajärvi
NWNicky J. Willis
Nicky J. Willis
KGKathryn Gilroy
Kathryn Gilroy
OSOwen Sansom
Owen Sansom

15 August 2018 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
TBThomas G. Bird
Thomas G. Bird
MMMiryam Müller
Miryam Müller
LBLuke Boulter
Luke Boulter
DVDavid F. Vincent
David F. Vincent
RRRachel A. Ridgway
Rachel A. Ridgway
SFStuart J. Forbes
Stuart J. Forbes
Inhibiting acute injury–induced senescence mediated by TGFβ signaling in regenerative epithelium improves liver regeneration.

20 June 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BKBjörn Kruspig
Björn Kruspig
TMTiziana Monteverde
Tiziana Monteverde
SNSarah Neidler
Sarah Neidler
AHAndreas Hock
Andreas Hock
EKEmma Kerr
Emma Kerr
Daniel J. MurphyDaniel J. Murphy
Daniel J. Murphy
KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung cancer. Activating mutations in KRAS are thought to confer independence from upstream signaling; however, recent data suggest that this independence may not be absolute. We show that initiation and progression of KRAS-driven lung tumors require input from ERBB family receptor tyrosine kinases (RTKs): Multiple ERBB RTKs are expressed and active from the earliest stages of KRAS-driven lung tumor development, and treatment with a multi-ERBB inhibitor suppresses formation of KRASG12D-driven lung tumors. We present evidence that ERBB activity amplifies signaling through the core RAS pathway, supporting proliferation of KRAS-mutant tumor cells in culture and progression to invasive disease in vivo. Brief pharmacological inhibition of the ERBB network enhances the therapeutic benefit of MEK (mitogen-activated protein kinase kinase) inhibition in an autochthonous tumor setting. Our data suggest that lung cancer patients with KRAS-driven disease may benefit from inclusion of multi-ERBB inhibitors in rationally designed treatment strategies.

13 November 2024 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
CKChristos Kiourtis
Christos Kiourtis
MTMaria Terradas-Terradas
Maria Terradas-Terradas
LGLucy M. Gee
Lucy M. Gee
SMStephanie May
Stephanie May
AGAnastasia Georgakopoulou
Anastasia Georgakopoulou
TBThomas G. Bird
Thomas G. Bird
Cellular senescence is not only associated with ageing but also impacts physiological and pathological processes, such as embryonic development and wound healing. Factors secreted by senescent cells affect their microenvironment and can induce spreading of senescence locally. Acute severe liver disease is associated with hepatocyte senescence and frequently progresses to multi-organ failure. Why the latter occurs is poorly understood. Here we demonstrate senescence development in extrahepatic organs and associated organ dysfunction in response to liver senescence using liver injury models and genetic models of hepatocyte-specific senescence. In patients with severe acute liver failure, we show that the extent of hepatocellular senescence predicts disease outcome, the need for liver transplantation and the occurrence of extrahepatic organ failure. We identify the TGFβ pathway as a critical mediator of systemic spread of senescence and demonstrate that TGFβ inhibition in vivo blocks senescence transmission to other organs, preventing liver senescence induced renal dysfunction. Our results highlight the systemic consequences of organ-specific senescence, which, independent of ageing, contributes to multi-organ dysfunction.